Opthea Limited
1 day chart
Get A$10 trading credit to start you off
Sign up and fund a new Stake AUS account and enjoy an extra A$10 trading credit on us.
Sign up and fund a new Stake AUS account and get A$10 bonus trading credit.
T&Cs apply
About OPT
Opthea Limited (OPT) is currently running two Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab). These trials are being held at multiple locations, with participants randomly assigned and neither the participants nor the researchers knowing which treatment is given. The purpose is to check the safety and better results of sozinibercept when used together with current anti-VEGF-A treatments for wet AMD. Opthea's Phase 3 program is planned to support a wide usage approval. If the trials go well, sozinibercept may be cleared for use with any anti-VEGF-A drug for treating wet AMD.
Find out what a historical investment in Opthea Limited would be worth today using our OPT stock calculator.
Sector
Health Care
CEO
Dr Frederic Guerard
Industry
Biotechnology
Website
opthea.com
$739M
-1.15
-
$0.62
$0.60
$0.60
$1.17
$0.37
Ready to start your investing journey with Stake?
Open an accountAnnouncements
OPT FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in OPT
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in OPT
on Stake
Buy OPT from A$3 brokerage
Invest in 2,500+ Aussie stocks and ETFs
CHESS-sponsored ASX trades
